Berry Genomics Co Ltd

Berry Genomics operates with a capital structure that includes total liabilities of CNY 807.99 million and total equity of CNY 1.48 billion, resulting in a debt-to-equity ratio of 0.19, which is relatively low compared to industry norms. The company's liquidity position is characterized by a current ratio of 1.96, indicating a moderate ability to meet short-term obligations. However, the company reported negative free cash flow of CNY -187.67 million, which suggests that it is not generating sufficient cash from operations to fund its capital expenditures and other operational needs. Profitability metrics for Berry Genomics are concerning, with a return on equity (ROE) of -13.33% and a return on assets (ROA) of -8.62%. These figures indicate that the company is not generating returns that meet the cost of capital, and its performance is below the typical thresholds for the medical equipment and supplies industry. The company's operating income was negative at CNY -187.58 million, and its net income was also negative at CNY -196.84 million, reflecting significant operational challenges. The company's revenue is primarily concentrated in its core genomic sequencing services, with no disclosed geographic diversification in the provided data. This lack of geographic segmentation suggests that the company's revenue is not spread across multiple regions, which could expose it to regional economic or regulatory risks. The absence of detailed segment reporting limits the ability to assess the performance of different business lines or geographic areas. Looking at the company's growth trajectory, there is no specific outlook provided for the current or next fiscal year. However, the negative net income and free cash flow suggest that the company is not currently experiencing positive growth. The company's capital expenditures of CNY -75.68 million indicate ongoing investment in its operations, but the negative free cash flow implies that these investments are not yet generating sufficient returns. The risk assessment for Berry Genomics highlights a medium liquidity risk and a low dilution risk. The company's liquidity risk is primarily due to its negative free cash flow and the fact that its net cash is negative after subtracting total debt. The dilution risk is low, as there is no indication of significant share issuance or dilution potential in the near term. The company's financial structure and performance suggest that it may need to seek additional financing to support its operations, which could introduce new risks. Recent events and filings for Berry Genomics are not detailed in the provided data. However, the company's financial performance, as reflected in its negative net income and free cash flow, suggests that it may be facing operational or market challenges. The absence of specific recent events or filings limits the ability to assess the company's current strategic direction or any new initiatives that may be in place.